List view / Grid view
9 October 2014 | By On Broadcast
18 years since the first cord blood transplants were performed in the UK, public knowledge on this life-saving process is still sorely lacking. A study of over 4,000 people found that nearly a third (32%) of Britons did not know you can store umbilical cord blood and tissue, while the…
9 October 2014 | By kdm communications
Avacta’s Optim® 2 platform is an innovative analytical instrument designed to probe multiple protein stability indicating parameters at high speed using ultra-low sample volumes...
9 October 2014 | By kdm communications
Dolomite Microfluidics, a sister company to flow chemistry specialist Syrris, has developed an innovative range of Micro Droplet Systems for automatic, seamless production of monodispersed droplets...
8 October 2014 | By B&W Tek
B&W Tek, is pleased to announce new enhancements to its NanoRam® handheld Raman spectrometer...
8 October 2014 | By GlobalData
Gilead’s announcement of positive Phase III results for its investigational single-tablet regimen (STR), elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (TAF), caps a series of developments bolstering the company’s position as HIV treatment market leader...
8 October 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company has successfully resolved all outstanding U.S. patent litigation relating to efavirenz, an active ingredient contained in our Sustiva (efavirenz) and Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) products...
8 October 2014 | By The Wellcome Trust, The Institute of Cancer Research & Merck Serono
Merck Serono, The Institute of Cancer Research, and the Wellcome Trust, London, have announced a co-development and license agreement building on two independent research programs at both the ICR and Merck Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family...
8 October 2014 | By Allied Minds
Allied Minds announced the launch of Novare Pharmaceuticals, a biotechnology company focused on developing therapeutic products that help the body replenish and rebuild itself using its own tissue through the modulation of RHAMM...
8 October 2014 | By OBN and EMIG
OBN and EMIG have called on the UK government to allocate additional funding to support the industrial component of Innovate UK’s Biomedical Catalyst...
8 October 2014 | By Ubiquigent and University of Dundee
Agreement brings together expertise to design, develop and market small molecule libraries targeting ubiquitin system proteins...
7 October 2014 | By Medical Research Council
Three ambitious new research programmes, which aim to deliver a step-change in our understanding of disease by using human volunteers in experimental studies, have been funded as part of a £60m investment from the Medical Research Council...
7 October 2014 | By Embo Medical
Early-stage medical device company is developing minimally invasive embolization technology for the treatment of wide variety of diseases...
6 October 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced the appointment of Mr Urs Rohner to its Board as a Non-Executive Director, effective 1 January 2015...
6 October 2014 | By Novartis
Novartis announced that it has entered into a clinical collaboration with Bristol-Myers Squibb Company to evaluate the safety, tolerability and preliminary efficacy of three molecularly targeted compounds in combination with Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor...
6 October 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and The University of Texas MD Anderson Cancer Center announced a novel clinical research collaboration to evaluate multiple immunotherapies...
